Effects of Dehydroepiandrosterone on In Vitro Fertilization Among Women Aging Over 35 Years and Normal Ovarian Reserve

  • Fatemeh Mostajeran Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Hatav Tehrani Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Elham Ghoreishi Mail Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Keywords:
Dehydroepiandrosterone, IVF, Infertility

Abstract

Objective: The fertility potential of women declines with aging and the likelihood of infertility and stillbirth increase. Treatment protocols involving dehydroepiandrosterone (DHEA) provide pathways on improving fertility and live birth rate. This randomized clinical trial aimed to evaluate the effect of DHEA on In Vitro Fertilization (IVF) outcomes in women over 35 years and normal ovarian reserve.Materials and methods: One hundred and six consecutive women with advanced reproductive age undergoing IVF due to infertility were enrolled in the study. Participants in the intervention group received 75 mg/day of DHEA orally 8 weeks before starting the cycle of ovulation induction. Participants in placebo group received placebo tablets during the same period. After 8 weeks, routine procedure of IVF was initiated then Clinical pregnancy, Miscarriage, Endometrial thickness and Duration of stimulation were evaluated for all the participants in both groups.Results: There is no significant difference between groups in terms of age and BMI. Mean endometrial thickness was significantly lower in DHEA group (9.63 ± 0.70vs.8.05 ± 0.70; p < 0.001) while Duration of stimulation was higher (8.98 ± 1.29vs.10.59 ± 1.43; p < 0.001). There was no significant difference between pregnancy rate, and miscarriage rate of the groups.Conclusion: According to the result of this study, DHEA supplementation may improve IVF outcomes in infertile women. Although additional larger and placebo-controlled studies using different DHEA protocols are required to support our present findings.  

References

References:

Broekmans F, Soules M, Fauser B. Ovarian aging: mechanisms and clinical consequences. Endocrine reviews. 2009;30(5):465-93.

_______________________________________________________

Tartagni M, Cicinelli MV, Baldini D, Tartagni MV, Alrasheed H, DeSalvia MA, et al. Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old. Reproductive Biology and Endocrinology. 2015;13(1):18.

___________________________________________________

Cabry R, Merviel P, Hazout A, Belloc S, Dalleac A, Copin H, et al. Management of infertility in women over 40. Maturitas. 2014;78(1):17-21.

_____________________________________________________

Arlt W. Dehydroepiandrosterone and ageing. Best Practice & Research Clinical Endocrinology & Metabolism. 2004;18(3):363-80.

___________________________________________________

Casson P, Lindsay M, Pisarska M, Carson S, Buster J. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Human Reproduction. 2000;15(10):2129-32.

_______________________________________________________

Gleicher N, Weghofer A, Barad DH. Improvement in diminished ovarian reserve after dehydroepiandrosterone supplementation. Reproductive biomedicine online. 2010;21(3):360-5.

______________________________________________________

Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. Journal of assisted reproduction and genetics. 2007;24(12):629-34.

___________________________________________________

Sönmezer M, Özmen B, Cil A, Özkavukçu S, Taşçı T, Olmuş H, et al. Dehydroepiandrosterone supplementation improves ovarian response and cycle outcome in poor responders. Reproductive biomedicine online. 2009;19(4):508-13.

___________________________________________________

Saghaei M. Random allocation software for parallel group randomized trials. BMC medical research methodology. 2004;4(1):26.

_____________________________________________________

Tartagni M, De pergola G, Pellegrino A, Baldini D, et al. Potential benefit of dehydroepiandrosterone supplementation for infertile but not poor responder patients in a IVF program. Minerva Ginecol. 2014;67(1):7-12.

____________________________________________________

Brad D, Gleicher N. Effect of dehidroepiandrosterone on oocyte and embryo grade and cell number in IVF. Hum Reprod 2006;21:2845-9.

_______________________________________________________

Wiser A, Gonen O, Ghetler Y,et al. Addition of dehydroepiandrosterone for poor responder patients before and during IVF treatment improves the pregnancy rate: a randomizied prospective study. Hum Reprod 2010;25:2496-500.

_____________________________________________________

Nark Wichean A, Maalouf W, Campbell BK, et al. Efficacy of dehydroepiandrosterone to improve ovarian response in women with diminished ovarian reserve: a meta analysis. Reprod Biol Endocrinol2013;11:44.

_____________________________________________________

Xu B, Li Z, Yue J, et al. Effect of dehydroepiandrosterone adminstration in patients with poor ovarian response according to the Bologna criteria. PLOS ONE 2014;9:e99858.

_____________________________________________________

Glecher N, Weghofer A, Barod DH. The role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment? Reprod Biol Endocrinol 2011;9:116.

_____________________________________________________

Liu X, Wang W, Wang X, et al. Effect of dehydroepiandrosterone adminstration in chinese women over 37 years undergoing assisted reproductive techniques. European Jornal of Obstetrics & Gynecology and Reproductive Biology 2016;9:13.

Published
2019-02-05
How to Cite
1.
Mostajeran F, Tehrani H, Ghoreishi E. Effects of Dehydroepiandrosterone on In Vitro Fertilization Among Women Aging Over 35 Years and Normal Ovarian Reserve. J Fam Reprod Health. 12(3):129-133.
Section
Original Articles